PRL-2903-treated T2D rats had similar C-peptide levels as the vehicle—treated T2D rats at baseline, with values dropping slightly but significantly more in the PRL-2903-treated T2D group (p < 0.001). This evidence concerns the gene PRL and type 2 diabetes mellitus.